Editas Medicine (EDIT) Tops Q1 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to Editas Medicine (EDIT) Tops Q1 EPS by 5c

Editas Medicine Announces First Quarter 2022 Results and Business Updates

May 4, 2022 6:45 AM EDT

Appointed Gilmore ONeill as CEO effective June 1, 2022; James C. Mullen to serve as Executive Chairman

First pediatric patient dosed in Phase 1/2 BRILLIANCE trial of EDIT-101 for LCA10; clinical data update expected in 2H 2022

On track to dose first SCD patient in 1H 2022 and first TDT patient by year-end with EDIT-301; initial SCD data expected by year-end

Preclinical data demonstrated that edited iNK cells increased persistence, enhanced anti-tumor activity, and extended survival, supporting continued development as a novel therapeutic approach for solid tumors

... More